[go: up one dir, main page]

WO2004078748A3 - Novel bicyclic urea derivatives useful in the treatment of cancer and other disorders - Google Patents

Novel bicyclic urea derivatives useful in the treatment of cancer and other disorders Download PDF

Info

Publication number
WO2004078748A3
WO2004078748A3 PCT/US2004/006287 US2004006287W WO2004078748A3 WO 2004078748 A3 WO2004078748 A3 WO 2004078748A3 US 2004006287 W US2004006287 W US 2004006287W WO 2004078748 A3 WO2004078748 A3 WO 2004078748A3
Authority
WO
WIPO (PCT)
Prior art keywords
disorders
cancer
treatment
urea derivatives
derivatives useful
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/US2004/006287
Other languages
French (fr)
Other versions
WO2004078748A2 (en
Inventor
Jacques Dumas
Stephen Boyer
Sharad Verma
Lila Adnane
Yuanwei Chen
Wendy Lee
Barton Phillips
Roger A Smith
William J Scott
Jennifer Burke
Jianqing Chen
Zhi Chen
Jianmei Fan
Karl Miranda
Brian Raudenbush
Aniko Redman
Jianxing Shao
Ning Su
Gan Wang
Lin Yi
Qingming Zhu
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Bayer Pharmaceuticals Corp
Original Assignee
Bayer Pharmaceuticals Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bayer Pharmaceuticals Corp filed Critical Bayer Pharmaceuticals Corp
Priority to MXPA05009104A priority Critical patent/MXPA05009104A/en
Priority to EP04716166A priority patent/EP1608639A2/en
Priority to CA2516931A priority patent/CA2516931C/en
Priority to JP2006508978A priority patent/JP5229853B2/en
Publication of WO2004078748A2 publication Critical patent/WO2004078748A2/en
Publication of WO2004078748A3 publication Critical patent/WO2004078748A3/en
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/78—Carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C07D213/81—Amides; Imides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Pyridine Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

This invention relates to novel diary) ureas, pharmaceutical compositions containing such compounds and the use of those compounds or compositions for treating hyper-proliferative and angiogenesis disorders, as a sole agent or in combination with cytotoxic therapies.
PCT/US2004/006287 2003-02-28 2004-03-01 Novel bicyclic urea derivatives useful in the treatment of cancer and other disorders Ceased WO2004078748A2 (en)

Priority Applications (4)

Application Number Priority Date Filing Date Title
MXPA05009104A MXPA05009104A (en) 2003-02-28 2004-03-01 Novel bicyclic urea derivatives useful in the treatment of cancer and other disorders.
EP04716166A EP1608639A2 (en) 2003-02-28 2004-03-01 Novel bicyclic urea derivatives useful in the treatment of cancer and other disorders
CA2516931A CA2516931C (en) 2003-02-28 2004-03-01 Novel bicyclic urea derivatives useful in the treatment of cancer and other disorders
JP2006508978A JP5229853B2 (en) 2003-02-28 2004-03-01 Novel bicyclic urea derivatives useful for the treatment of cancer and other diseases

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US45034803P 2003-02-28 2003-02-28
US60/450,348 2003-02-28

Publications (2)

Publication Number Publication Date
WO2004078748A2 WO2004078748A2 (en) 2004-09-16
WO2004078748A3 true WO2004078748A3 (en) 2004-11-11

Family

ID=32962496

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2004/006287 Ceased WO2004078748A2 (en) 2003-02-28 2004-03-01 Novel bicyclic urea derivatives useful in the treatment of cancer and other disorders

Country Status (5)

Country Link
EP (1) EP1608639A2 (en)
JP (1) JP5229853B2 (en)
CA (1) CA2516931C (en)
MX (1) MXPA05009104A (en)
WO (1) WO2004078748A2 (en)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8637553B2 (en) 2003-07-23 2014-01-28 Bayer Healthcare Llc Fluoro substituted omega-carboxyaryl diphenyl urea for the treatment and prevention of diseases and conditions
US9181188B2 (en) 2002-02-11 2015-11-10 Bayer Healthcare Llc Aryl ureas as kinase inhibitors

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8124630B2 (en) 1999-01-13 2012-02-28 Bayer Healthcare Llc ω-carboxyaryl substituted diphenyl ureas as raf kinase inhibitors
ES2384160T3 (en) 1999-01-13 2012-07-02 Bayer Healthcare Llc Diphenyl ureas substituted with omega-carboxy aryl as kinase inhibitors p38
AU2003209116A1 (en) 2002-02-11 2003-09-04 Bayer Pharmaceuticals Corporation Aryl ureas with angiogenesis inhibiting activity
ES2288694T3 (en) * 2003-05-20 2008-01-16 Bayer Pharmaceuticals Corporation DIARIL UREAS FOR DISEASES MEDIATED BY THE RECEIVER OF THE GROWTH FACTOR DERIVED FROM PLATES.
US7071182B2 (en) * 2003-12-23 2006-07-04 Abbott Laboratories Antagonists of melanin concentrating hormone effects on the melanin concentrating hormone receptor
CA2557398A1 (en) * 2004-02-26 2005-09-09 Hans-Peter Buchstaller Benzimidazolyl derivatives as kinase inhibitors
EP1799661A1 (en) * 2004-10-08 2007-06-27 AstraZeneca AB New hydroxymethylbenzothiazoles amides
HRP20100674T1 (en) 2005-03-07 2011-01-31 Bayer Schering Pharma Aktiengesellschaft PHARMACEUTICAL PREPARATION CONTAINING OMEGA-CARBOXYARIL SUBSTITUTED DIPHENYL UREA FOR CANCER TREATMENT
BRPI0502016B8 (en) * 2005-06-03 2021-05-25 Univ Federal Do Rio De Janeiro Ufrj ureid compounds, pharmaceutical compositions containing them and their use in the treatment of inflammatory diseases
CA2648785A1 (en) 2006-03-23 2007-09-27 Prolysis Ltd. Antibacterial agents
DE102006029795A1 (en) * 2006-06-27 2008-01-03 Schebo Biotech Ag New urea derivatives and their uses
JP2010514692A (en) 2006-12-20 2010-05-06 バイエル ヘルスケア リミティド ライアビリティ カンパニー Hydroxymethylphenylpyrazolylurea compounds useful for the treatment of cancer
CL2008002384A1 (en) 2007-08-15 2009-07-17 Glaxo Group Ltd Compounds derived from quinolinyloxypiperidine and pyrrolidine, pharmaceutical composition, pharmaceutical combination, useful for the treatment of inflammatory and / or allergic diseases of the respiratory tract.
CN102295600A (en) * 2011-09-08 2011-12-28 天津大学 Method for preparing 5-amino-8-hydroxyquinoline
WO2013138753A1 (en) 2012-03-16 2013-09-19 Fox Chase Chemical Diversity Center, Inc. Prodrugs of riluzole and their method of use
CN103508961B (en) 2012-06-26 2015-07-22 中美冠科生物技术（太仓）有限公司 Antitumor drug
CN104250226B (en) * 2013-06-27 2019-04-26 常州方楠医药技术有限公司 A method of preparing Rui Gefeini intermediate
WO2017047803A1 (en) * 2015-09-17 2017-03-23 三栄源エフ・エフ・アイ株式会社 Production method for polysaccharide thickener-containing preparation
CN110072526A (en) * 2016-08-17 2019-07-30 西奈山伊坎医学院 Kinase inhibitor compounds, compositions and methods for treating cancer
TWI822140B (en) * 2021-06-24 2023-11-11 南韓商Ｌｇ化學股份有限公司 Novel pyridine derivative compound as ron inhibitors

Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1999024035A1 (en) * 1997-11-10 1999-05-20 Bristol-Myers Squibb Company Benzothiazole protein tyrosine kinase inhibitors
WO1999032106A1 (en) * 1997-12-22 1999-07-01 Bayer Corporation Inhibition of raf kinase using substituted heterocyclic ureas
WO2000042012A1 (en) * 1999-01-13 2000-07-20 Bayer Corporation φ-CARBOXYARYL SUBSTITUTED DIPHENYL UREAS AS RAF KINASE INHIBITORS
WO2001036403A1 (en) * 1999-11-16 2001-05-25 Boehringer Ingelheim Pharmaceuticals, Inc. Urea derivatives as anti-inflammatory agents
WO2002062763A2 (en) * 2001-02-07 2002-08-15 Bayer Corporation Inhibition of raf kinase using quinolyl isoquinolyl or pyridyl ureas
WO2003068228A1 (en) * 2002-02-11 2003-08-21 Bayer Pharmaceuticals Corporation Aryl ureas with angiogenesis inhibiting activity

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6001930A (en) 1997-03-13 1999-12-14 Acushnet Company Golf ball forming compositions comprising polyamide blended with sulfonated or phosphonated polymers
RU2265597C2 (en) 1997-12-22 2005-12-10 Байер Копэрейшн Aryl- and heteroaryl-substituted heterocyclic derivatives of urea, method for inhibition of raf kinase activity and pharmaceutical composition
IL136690A0 (en) 1997-12-22 2001-06-14 Bayer Ag Inhibition of raf kinase using symmetrical and unsymmetrical substituted diphenyl ureas
ES2154253T3 (en) 1997-12-22 2012-01-27 Bayer Healthcare Llc INHIBITION OF THE ACTIVITY OF P38 CINASA USING REPLACED HETEROCYCLIC UREAS.
IL136768A0 (en) 1997-12-22 2001-06-14 Bayer Ag INHIBITION OF p38 KINASE ACTIVITY USING ARYL AND HETEROARYL SUBSTITUTED HETEROCYCLIC UREAS
DK1042305T3 (en) 1997-12-22 2005-09-19 Bayer Pharmaceuticals Corp Inhibition of p38 kinase using symmetric and asymmetric diphenylureas
US20020065296A1 (en) * 1999-01-13 2002-05-30 Bayer Corporation Heteroaryl ureas containing nitrogen hetero-atoms as p38 kinase inhibitors
ES2384160T3 (en) * 1999-01-13 2012-07-02 Bayer Healthcare Llc Diphenyl ureas substituted with omega-carboxy aryl as kinase inhibitors p38
RU2319693C9 (en) * 1999-01-13 2008-08-20 Байер Копэрейшн Derivatives of urea (variants), pharmaceutical composition (variants) and method for treatment of diseases associated with cancer cells growth (variants)
KR100878774B1 (en) 2001-04-18 2009-01-14 유로-셀티크 소시에떼 아노뉨 Nociceptin analogs
CA2443950C (en) * 2001-04-20 2011-10-18 Bayer Corporation Inhibition of raf kinase using quinolyl, isoquinolyl or pyridyl ureas
CA2516627A1 (en) * 2003-02-28 2004-09-16 Bayer Pharmaceuticals Corporation Substituted pyridine derivatives useful in the treatment of cancer and other disorders

Patent Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1999024035A1 (en) * 1997-11-10 1999-05-20 Bristol-Myers Squibb Company Benzothiazole protein tyrosine kinase inhibitors
WO1999032106A1 (en) * 1997-12-22 1999-07-01 Bayer Corporation Inhibition of raf kinase using substituted heterocyclic ureas
WO2000042012A1 (en) * 1999-01-13 2000-07-20 Bayer Corporation φ-CARBOXYARYL SUBSTITUTED DIPHENYL UREAS AS RAF KINASE INHIBITORS
WO2001036403A1 (en) * 1999-11-16 2001-05-25 Boehringer Ingelheim Pharmaceuticals, Inc. Urea derivatives as anti-inflammatory agents
WO2002062763A2 (en) * 2001-02-07 2002-08-15 Bayer Corporation Inhibition of raf kinase using quinolyl isoquinolyl or pyridyl ureas
WO2003068228A1 (en) * 2002-02-11 2003-08-21 Bayer Pharmaceuticals Corporation Aryl ureas with angiogenesis inhibiting activity

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
DUMAS J: "PROTEIN KINASE INHIBITORS FROM THE UREA CLASS", CURRENT OPINION IN DRUG DISCOVERY AND DEVELOPMENT, CURRENT DRUGS, LONDON, GB, vol. 5, no. 5, 2002, pages 718 - 727, XP009011493, ISSN: 1367-6733 *
HOTTE S J ET AL: "BAY 43-9006: EARLY CLINICAL DATA IN PATIENTS WITH ADVANCED SOLID MALIGNANCIES", CURRENT PHARMACEUTICAL DESIGN, BENTHAM SCIENCE PUBLISHERS, SCHIPHOL, NL, vol. 8, no. 25, 2002, pages 2249 - 2253, XP001145745, ISSN: 1381-6128 *

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9181188B2 (en) 2002-02-11 2015-11-10 Bayer Healthcare Llc Aryl ureas as kinase inhibitors
US8637553B2 (en) 2003-07-23 2014-01-28 Bayer Healthcare Llc Fluoro substituted omega-carboxyaryl diphenyl urea for the treatment and prevention of diseases and conditions

Also Published As

Publication number Publication date
JP2006519265A (en) 2006-08-24
EP1608639A2 (en) 2005-12-28
WO2004078748A2 (en) 2004-09-16
MXPA05009104A (en) 2006-05-31
CA2516931C (en) 2014-09-09
CA2516931A1 (en) 2004-09-16
JP5229853B2 (en) 2013-07-03

Similar Documents

Publication Publication Date Title
WO2004078747A8 (en) Novel cyanopyridine derivatives useful in the treatment of cancer and other disorders
WO2004078748A3 (en) Novel bicyclic urea derivatives useful in the treatment of cancer and other disorders
WO2004078746A3 (en) 2-oxo-1,3,5-perhydrotriazapine derivatives useful in the treatment of hyper-proliferative, angiogenesis, and inflammatrory disorders
WO2007064931A3 (en) Substituted 4-amino-pyrrolotriazine derivatives useful for treating hyper-proliferative disorders and diseases associated with angiogenesis
TW200608979A (en) Pyrrolotriazine derivatives useful for treating hyper-proliferative disorders and diseases associated with angiogenesis
WO2004078128A3 (en) Substituted pyridine derivatives useful in the treatment of cancer and other disorders
MY191349A (en) New pharmaceutical compositions for the treatment of hyper-proliferative disorders
WO2007064883A3 (en) Substituted 4-amino-pyrrolotriazine derivatives useful for treating hyper-proliferative disorders and diseases associated with angiogenesis
EP1521749B8 (en) PHENYL-(4-(3-PHENYL-1H-PYRAZOL-4-YL)-PYRIMIDIN-2-Yl)-AMINE DERIVATIVES
WO2003080582A3 (en) Fredericamycin derivatives
TN2009000137A1 (en) Substituted 2,3-dihydroimidazo[1,2-c]quinazoline derivatives useful for treating hyper-proliferative disorders and diseases associated with angiogenesis
WO2004006858A3 (en) Compounds, compositions, and methods employing same
TW200800998A (en) Phenylalanine derivatives
WO2005110994A8 (en) Substituted pyrazolyl urea derivatives useful in the treatment of cancer
WO2005000217A3 (en) Combination therapy for the treatment of dyslipidemia
WO2005004818A3 (en) Heterocyclic compounds and their use as anticancer agents
WO2001012199A3 (en) Methoxyamine potentiation of temozolomide anti-cancer activity
WO2007064872A3 (en) Urea compounds useful in the treatment of cancer
PL1654253T3 (en) Substituted 3-pyrrolidin-indole derivatives
WO2005009460A3 (en) Pharmaceutical composition comprising activin a, alk-4 or derivatives thereof for the treatment of ophthalmic disorders or cancer
WO2004026836A3 (en) 1-pyridin-4-yl-urea derivatives
WO2006125539A3 (en) Combination therapy comprising diaryl ureas for treating diseases
WO2005118601A3 (en) Sulfonylethyl phosphorodiamidates for use in the treatment of cancer
WO2004073615A3 (en) Deazaflavin compounds and methods of use thereof
WO2004087880A8 (en) Compounds and their use to treat diabetes and related disorders

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BW BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE EG ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NA NI NO NZ OM PG PH PL PT RO RU SC SD SE SG SK SL SY TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): BW GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LU MC NL PL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
WWE Wipo information: entry into national phase

Ref document number: 2516931

Country of ref document: CA

WWE Wipo information: entry into national phase

Ref document number: 2006508978

Country of ref document: JP

WWE Wipo information: entry into national phase

Ref document number: PA/a/2005/009104

Country of ref document: MX

Ref document number: 2004716166

Country of ref document: EP

WWP Wipo information: published in national office

Ref document number: 2004716166

Country of ref document: EP